NEW YORK, June 3 /PRNewswire-FirstCall/ -- American Oriental Bioengineering (NYSE: AOB) today announced that it plans to make a private offer, subject to market conditions and other factors, to sell approximately $125 million in aggregate liquidation preference of newly issued convertible preferred stock. The convertible preferred stock is contingently putable, will pay dividends quarterly in arrears, and will be convertible upon the occurrence of specified events into cash, shares of the Company's common stock or a combination of cash and shares of the Company's common stock, at the Company's option.
The Company intends to grant the initial purchasers of the preferred stock an option to purchase up to an additional $25 million in aggregate liquidation preference of the preferred stock to cover overallotments.
The Company anticipates using the net proceeds from the offering for working capital; general corporate purposes; repurchases of outstanding capital stock; to fund a prepaid forward contract the Company may enter into; and possible acquisitions of and investments in complementary businesses and products.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any securities, and shall not constitute an
offer, solicitation or sale in any jurisdiction in which such offering
would be unlawful. The preferred stock, and any common stock issuable upon
conversion of the preferred stock, have not been registered under the
Securities Act of 1933 or the securities laws of any other jurisdiction and
may not be offered or sold in the United States without registration or an
applicable exemption from the registration requirements of the Securities
Act of 1933 and applicable state securit
|SOURCE American Oriental Bioengineering, Inc.|
Copyright©2008 PR Newswire.
All rights reserved